Progress in Drug Research and Application of PET tumor.docVIP

 PAGE \* MERGEFORMAT 19 Progress in Drug Research and Application of PET tumor Abstract In recent years, positron radionuclide and its diagnosis and treatment of radioactive labeled drug is extremely active in research and application. With the penetration of molecular biology into the field of nuclear medicine and PET or PET / CT technology, positron radionuclides and their labeled radiopharmaceuticals have entered a rapid development stage. Articles on tumor drugs and their clinical application of positron are reviewed. Keywords: Positron emission tomography radiopharmaceutical nuclide In recent years, positron emission tomography imaging (positron emission tomography, PET) research has developed rapidly and have made gratifying achievements. This is our nuclear medicine a new milestone in the history of another [1]. So far, nearly 60 units nationwide PET and PET / CT, nearly 100 more than in line with single photon emission computed tomography imaging equipment (single photon emission computed tomography with coincidence detection, SPECT with coincidence) to run, according to preliminary statistics have been completed Tens of thousands of cases of patient examination, their clinical value has been affirmed. PET imaging agent for various foreign as high as hundreds more, however, at present all of our PET imaging examination, application of PET drugs more than 95% of fluorine [18F] labeled fluoro-deoxy glucose (18F-FDG), This will undoubtedly greatly limits the real potential function and the role of PET. Therefore, the research and development with China’s intellectual property in today’s PET drug promotion and development of China’s PET, PET / CT the cause of the key. 1 PET radiopharmaceuticals with positron Overview PET imaging, including positron radionuclides and their labeled compounds, and PET tomography imaging equipment, is dispensable, PET radioactive drug development and utilization is one of the conditions th